A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation - Report - MDSpire

A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation

  • By

  • Chenlu Hou

  • Yifan Zhang

  • Xiangqi Cao

  • Yonglan Tang

  • Ting Gao

  • Baoli Tang

  • Ying Zhu

  • Zhe Ruan

  • Ting Chang

  • June 3, 2026

  • 0 min

Share

Clinical Report: Predictive Model for Low-Dose Rituximab Efficacy in MG

Overview

This study developed a predictive model to identify myasthenia gravis patients likely to benefit from low-dose rituximab. The model demonstrated moderate discriminative ability with an AUC of 0.777.

Background

Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness due to impaired neuromuscular transmission. Rituximab (RTX) has emerged as a treatment option for refractory cases, but its efficacy varies among patients. Developing predictive models is essential to optimize treatment strategies and improve patient outcomes.

Data Highlights

VariableImpact
New-onset MGSignificant predictor
Baseline MG-ADL scoreSignificant predictor
High CD19+/CD27+ B lymphocyte proportionSignificant predictor
High-dose prednisoneSignificant predictor
Early immunotherapy initiationSignificant predictor

Key Findings

  • The model achieved an AUC of 0.777, indicating moderate discriminative ability.
  • Patients in the high-probability group had a 6.52-fold higher likelihood of achieving minimal symptom expression (MSE).
  • Calibration curves indicated good alignment with the ideal curve for probabilities between 0 and 0.7.
  • Five key variables were identified as predictors of RTX efficacy.
  • Internal validation was performed using bootstrap resampling methods.

Clinical Implications

The predictive model can assist clinicians in identifying patients with AChR-MG who are more likely to benefit from low-dose rituximab.

Conclusion

The developed nomogram serves as a tool for predicting treatment outcomes in myasthenia gravis patients receiving low-dose rituximab.

Related Resources & Content

  1. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update - PMC
  2. Rituximab treatment in myasthenia gravis
  3. Heavy Chain H3 of Inter-alpha-trypsin Inhibitor as a Potential Indicator of Disease Activity in Myasthenia Gravis
  4. Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study
  5. Complement Activation at the Neuromuscular Junction in Seronegative Myasthenia Gravis
  6. Bone Marrow Transplantation — Previous Antibiotic Use as a Predictor of Early and Extended Hematologic Toxicity and Outcomes in Acute B-Cell Leukemia Patients Undergoing CD19 CAR T-Cell Therapy
  7. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update - PMC
  8. Rituximab treatment in myasthenia gravis
  9. Frontiers | Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis

Original Source(s)

A predictive model for low-dose rituximab response in anti-acetylcholine receptor antibody-positive myasthenia gravis: establishment and validation

  • by Chenlu Hou, Yifan Zhang, Xiangqi Cao, Yonglan Tang, Ting Gao, Baoli Tang, Ying Zhu, Zhe Ruan, Ting Chang

  • June 3, 2026

Related Content

Cognition Associated With Future Depression Risk

Lower cognition is associated with later depression in controls, while higher cognition is associated with relapse in remitted depression

Early Neurodevelopmental Outcomes in Pediatric Congenital Heart Disease

In a multicenter registry study, genetic diagnoses were associated with substantially lower cognitive, language, and motor scores; while birth weight, surgical timing, hospitalization burden, and caregiver education were also associated with outcomes.

Spinal and supraspinal mechanisms of chronic itch: from neuronal circuits to the neuro-immune-microbial axis